Evidence for renal vasodilation in pre-dialysis patients during correction of anemia by erythropoietln Results from animal experiments have suggested that treatment with recombinant human erythropoietin (rHuEPO) causes changes in renal hemodynamics which are detrirnental to renal function. Therefore, the effects of correction of the anemia by rHuEPO on glomerular filtration rate (GFR; inulin clearance) and effective renal plasma flow (ERPF; PAH clearance) were studied in eight pre-dialysis patients. The studies were done before (Hct 0,24 0.05 liter/liter) and at 89 19 days after the start of rHuEPO therapy (Hct 0.39 0.03 liter/liter). To further evaluate the effects of ACE inhibition, 25 mg of captopril was given orally after baseline values had been obtained. Baseline GFR, renal blood flow (RBF) and filtration fraction (FF) did not change during rHuEPO therapy. At low hematocrit (Hct) captopril induced a significant increase in ERPF and RBF, and a decrease in MAP. After correction of the hematocrit the blood pressure lowering effect of captopril remained unchanged. However, captopril no longer induced changes in ERPF and RBF. We conclude that the increase in hematocrit had no adverse effects on GFR. The results suggest that changes in hematocrit may influence the effects of ACE inhibition on efferent vascular resistance. Therefore, the hematocrit should be taken into account when evaluating studies on the effects of ACE inhibition in the progression of chronic renal failure.
The introduction of recombinant human erythropoietin (rHuEPO) for the treatment of the anemia of chronic renal failure has renewed the interest in the effects of changes in hematocrit on hemodynamics and renal function [1] [2] [3] [4] [5] . A major adverse event associated with rHuEPO therapy is the increase in blood pressure. The hematocrit is the major determinant of blood viscosity at high and low rates of shear [6] . The increase in whole blood viscosity and the loss of hypoxic vasodilation, resulting in an inappropriate increase in systemic vascular resistance, are suggested as potential causes of the increased blood pressure [7] .
Besides the adverse effects of systemic hypertension with regard to renal function, the increased hematocrit by itself also might affect the rate of progression of renal failure. Efferent arterioles are smaller in caliber and longer than afferent arterioles. According to Poiseuille's law, the increase in viscosity will cause a larger rise in efferent than in afferent vascular resistance. Also, due to ultrafiltration of plasma water in the glomerulus, hematocrit in the efferent arteriole always exceeds Received for publication June 4, 1991 and in revised form September 16, 1991 Accepted for publication September 23, 1991 © 1992 by the International Society of Nephrology hematocrit in the afferent arteriole [8] . This results in a disproportionate, passive increase in efferent vascular resistance. Changes in activity of the renin-angiotensin system also may play an active role, since plasma renin levels in dogs increase when hematocrit rises [9] .
In agreement with these theoretical considerations, important effects of hematocrit on renal hemodynamics were observed in patients with congenital cyanotic heart disease and cor pulmonale [10, 11] . In these patients renal blood flow (RBF), and effective renal plasma flow (ERPF) were considerably reduced. Since glomerular filtration rate (GFR) decreased to a smaller extent, this resulted in an increased filtration fraction (FF). Alter acute reduction of the hematocrit in these patients, RBF and ERPF increased, FF fell, and proteinuria decreased. Also in experimental animals, FF varies directly with systemic hematocrit, with proportionally greater changes in ERPF than in GFR [12] . More direct evidence for the influence of hematocrit on changes in renal hemodynamics stems from micropuncture studies in rats. An acute increase in hematocrit, induced by isovolemic exchange transfusions, led to an increase in efferent arteriolar resistance, an increase in glomerular transcapillary hydraulic pressure gradient and an increase in FF [13] . These studies showed that changes in renal arteriolar vascular resistance cause the changes in ERPF and FF in response to variations in systemic hematocrit. The presence of continuous glomerular hypertension in the rat may cause the development of focal segmental glomerular sclerosis and renal failure even after limited renal ablation [14] . Increased glomerular capillary pressure also may contribute to the progression of renal failure in patients with renal disease [15] .
Recently, results of two studies in five-sixth riephrectomized rats treated with rHuEPO suggested that rHuEPO therapy may accelerate chronic renal failure, and worsen systemic hypertension and glomerular hypertension because of increased efferent arteriolar resistance [16, 17] . Up to now, clinical studies in patients with renal disease, although not specifically designed to evaluate renal function, did not report acceleration of the rate of progression of renal failure measured as the slope of inverse plasma creatinine concentration (l/l'Cr) versus time [2] [3] [4] [5] . Yet, the rate of decline in 11Cr may not accurately reflect the decline in GFR.
In the present study, we have investigated the effects of rHuEPO induced changes in hematocrit on renal function in pre-dialysis patients.
Methods

Patients
Eight patients (four females, four males) with a history of progressive chronic renal failure participated in the study. The underlying renal diseases were: chronic glonierulonephritis in three, congenital hypoplastic kidneys in one, chronic pyelonephritis in one, reflux nephropathy with uninephrectomy in one, and unknown renal disease in two patients. The mean (± SD) Ccr was 13 5 ml/min/l .73 m2. All patients were anemic with hematocrits ranging between 0.16 and 0.30 liter/liter. The median age was 33 years (range from 25 to 66 years). Hypertension was either absent (N = 4) or medically controlled (N = 4). Antihypertensive treatment consisted of metoprolol 200 mg daily (patient A), propanolol 3 dd 20 mg (patient C), atenolol 25 mg daily (patient F), or atenolol 25 mg and nifedipine 2 dd 20 mg (patient G). No ACE inhibitors were prescribed before or during the study. None of the patients had received blood transfusions within three months of the start of the study.
Dietary and medication regimens were stable for at least one month before study entry and attempts were made to keep them constant. The 24 hour excretion of sodium and urea did not change during the study period.
Methods
All patients gave written informed consent. The patients were given intravenous injections of rHuEPO three times a week for eight weeks. The patients were randomly assigned to receive either 50 (N 2), 100 (N = 3), or 150 (N 3) units of rHuEPO per kilogram of body weight. Mter the completion of this eight week period, rHuEPO was injected intravenously once a week. The dose was three times the dose given in the former period, adjusted for response. Renal function measurements were done before rHuEPO therapy and at 89 19 days after the start of rHuEPO therapy when the increased hematocrit was stable within the target range of 0.35 to 0.45 liter/liter for at least three weeks.
The patients did not take food or drugs from 12 hours before the start of the renal function measurements until the end of the study. Smoking was not allowed in the same period. The patients were in a half sitting position during the whole study, except for micturition. GFR (inulin clearance) and ERPF (PAH clearance) were measured using a continuous infusion technique. An isotonic solution of inulin (mutest0, Laevosan, Linz, Austria) and para-aminohippuric acid (PAH, Merck Sharp & Dohme, West Point, Pennsylvania, USA) in distilled water was used as described elsewhere [181. Blood and urine samples were simultaneously collected at 45 minute intervals. Prior to the infusion the patients were given an oral water load of 15 mllkg. Every next 45 minutes the urinary losses were replaced by an equivalent oral water load. If urine flow was less than 100 ml/45 mm an extra oral water load of 100 ml was given. Urine was collected by spontaneous micturition. Mean arterial pressure (MAP, mm Hg) was measured every 15 minutes using a calibrated automatic recorder (DynamapTM). The mean MAP of every 45 minute interval was calculated as the mean of the three recordings during that interval. Body weight was measured before and after the study. After having obtained baseline values, 25 mg of captopril was given orally at 210 minutes after the start of the infusion, and measurements were continued for another three hours. The mean value of the two 45-minute GFR and ERPF measurements obtained immediately before captopril was compared with the mean value of two 45-minute intervals starting 45 minutes after captopril. Clearances were calculated according to standard clearance formulas C =UV/P and expressed as ml per mm per 1.73 m2 body surface. The FF was calculated as l00• GFRJERPF, and RBF was estimated using the formula: RBF = ERPF/(lhematocrit). During steady state the intraindividual coefficients of variation of the inulin and PAH clearances were 6.5%, and 6.9%, respectively. The intraindividual coefficients of variation between two separate measurements were 9.6%, and 11.2%, respectively.
All results are expressed as means with standard deviations.
T-test procedures for paired samples and for independent samples were used for statistical analysis. Differences were considered significant at the 0.05 level.
Results
rHuEPO therapy increased the mean hematocrit value from 0.24 0.05 liter/liter to 0.39 0.03 liter/liter. In patient C, who had hypertension before rHuEPO therapy, the dose of propanolol was increased to 3 dd 40 mg after seven weeks of therapy because of increasing blood pressure. In another hypertensive patient (patient G) nifedipine was replaced by minoxidil (2 dd 5 mg) after six weeks of rHuEPO due to side effects. All four patients without antihypertensive medication prior to rHuEPO therapy remained normotensive. Under these conditions there were no significant changes of systolic, diastolic, or mean arterial blood pressure throughout the study period.
The individual data on renal function are given in Table 1 . Baseline GFR and FF were comparable before and during rHuEPO treatment ( Table 2 ). The RBF also remained unchanged, and the values of ERPF tended to decrease. These small changes in ERPF correlated well with the changes predicted from initial RBF and the change in hematocnt (r 0.83, P < 0.01). Moreover, in two patients in whom hematocrit values had returned to their initial values after eight months, the decreased value of ERPF at high hematocrit had also returned to the initial value, while RBF was unchanged (data not shown). During rHuEPO therapy there was no significant change in 24 hours proteinuria when compared with pre-treatment values.
Prior to rHuEPO therapy a single dose of 25 mg of captopril resulted in a significant increase in RBF, when compared to baseline values (Table 2) . Despite a small, but nonsignificant increase in GFR, FF decreased significantly. Mter correction of the hematocrit by rHuEPO therapy the blood pressure lowering effect of captopril was identical to that in the first study. However, the captopril-induced rise in RBF and ERPF had disappeared completely. Since GFR remained stable, a change in FF was also absent. In four patients who were not yet on dialysis after 35 I weeks of treatment with rHuEPO, the measurements were repeated. In these patients we observed that a reaction to captopril was still absent (data not shown). By contrast, in another patient, in whom hematocrit after eight months had returned to the initial value, the response to captopril which was absent during high hematocrit was present again. 1-hematocrit) . The first studies were done before rHuEPO therapy. The second studies were done after the hematocrit had reached the target range, and was stable for at least three weeks. a P < 0.05, Difference between parameter before and after captopril ' P < 0.05, C p = 0.07, Difference between changes after captopril before and after rHuEPO therapy
Discussion
Studies in five-sixth nephrectomized rats showed that anemia retards the development of proteinuna and glomerular injury and reduces systemic hypertension, whereas treatment with rHuEPO causes an acceleration of glomerular injury [17] . These findings suggested that full correction of anemia in pre-dialysis patients may prove harmful to residual renal function. However, in rats there was also a considerable rise in systemic blood pressure during rHuEPO therapy. The remnant kidney model is a hypertensive model, in which systemic hypertension induces glomerular capillary hypertension, which is the major factor contributing to glomerular injury, hyperfiltration being much less important [14] . In agreement with these findings it was recently shown that glomerular hyperfiltration was not accompanied by glomerular injury in a normotensive rat remnant kidney model [19] . Whether rHuEPO therapy without concomitant hypertension will cause identical injury in experimental animals has not been studied. Moreover, in the anemia-protection model the accompanying iron depletion may have protected against additional tubulointerstitial injury and renal function deterioration [20] .
Recently, a clinical study of rHuEPO therapy in pre-dialysis patients showed a significant increase in FF (0.27 0.17 to 0.33 0.22) in four weeks [21] . In these patients the mean hematocrit was only moderately increased from 0.21 0.025 to 0.27 0.024 liter/liter. More importantly, the mean MAP increased significantly from 119.3 18.3 to 134.1 15.2 mm Hg. Yet, this increase in blood pressure was probably also related to the fact that these patients received no antihypertensive treatment. In the present study the increase in hematocrit was larger, from 0.24 0.05 to 0.39 0.03 liter/liter in 15.4 3.7 weeks. In our patients mean blood pressure was lower, and was kept constant throughout the study. Despite the considerable change in hematocrit, no significant alterations of GFR, RBF, or FF were observed. Although a change in the rate of decline in renal function cannot be excluded, the results of this and another study [5] do not suggest that a considerable increase in hematocrit has a major influence on kidney function.
To investigate further the hemodynamic characteristics during treatment with rHuEPO, we studied the effects of a single 25 mg dose of captopnl on renal function. We were interested to see if the expected blocking effect of captopril on angiotensin Il-mediated efferent vasoconstriction would be influenced by a change in hematocrit. Before rHuEPO treatment there was a significant increase in RBF after captopril, with a concomitant decrease in FF. Surprisingly, after correction of the hematocrit, captopril no longer induced changes in RBF and FF, although the blood pressure lowering effect of captopnl was identical to that in the first study. In our study baseline RBF remained unchanged, indicating that total renal vascular resistance did not change. This can be explained by either no change in renal vascular resistances, or by an increased passive vascular resistance combined with a decreased vascular tone. The observation that the observed rise in RBF after captopril during anemia was absent when hematocrit had increased, favors the explanation that, with increasing hematocrit, RBF is maintained by the development of an efferent vasodilation that cannot be increased further by captopril. An additional effect of increasing hematocrit on afferent vascular resistance cannot be excluded. A captopril-induced efferent vasodilation with high hematoerit could have been masked by the concomitant decrease in blood pressure. However, since baseline blood pressure and the decrease in blood pressure after captopril were similar before and alter increasing the hematocrit, the observations still indicate different states. In one patient, in whom hematocrit after eight months had returned to the initial value, the previously disappeared response to captopril during high hematocrit was present again. Since blood pressure, body weight and antihypertensive drugs had not changed, this suggests that the changes observed are indeed mediated by the change in hematocrit.
One could argue that the PAH clearance does not adequately reflect renal plasma flow in patients with decreased renal function due to an incomplete extraction rate. Yet, even when PAH clearance would not estimate low renal plasma flow adequately when compared to situations with normal renal plasma flow, it is likely that changes in renal plasma flow would still be reflected in changes in PAH clearance.
Results of several animal studies suggest that ACE inhibitors are beneficial in reducing the rate of decline of GFR, by their specific effect on efferent vascular resistance, irrespective of their blood pressure lowering effect [22, 23] . Prospective, randomized trials using ACE inhibition in patients with renal disease are currently under way. With regard to these studies, our data suggest that changes in hematocrit may influence the effects of ACE inhibition on efferent vascular resistance. Therefore, the hematocrit should be taken into account when evaluating studies on the effects of ACE inhibition in the progression of chronic renal failure. Also, treatment with ACE inhibitors for hypertension developing during rHuEPO therapy would appear to offer no specific advantages above other antihypertensive drugs. The final answer to the question whether rHuEPO changes the natural course of progression of renal failure in patients with renal disease, can only be given by large prospective trials, including precise renal function measurements and appropriate dietary and blood pressure control.
